Product Details
Synonyms
CD27, TNFRSF7, S152, T14, Tp55
Source
Human CD27, His Tag (CD7-H522b) is expressed from human 293 cells (HEK293). It contains AA Thr 21 - Ile 192 (Accession # P26842-1).
Predicted N-terminus: Thr 21
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 21.1 kDa. The protein migrates as 35-47 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human CD27, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS

The purity of Human CD27, His Tag (Cat. No. CD7-H522b) is more than 85% and the molecular weight of this protein is around 32-47 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA

Immobilized Human CD27, His Tag (Cat. No. CD7-H522b) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD27 Ligand Protein, Avitag,Fc Tag with a linear range of 1-31 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
CD27 antigen
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
4 Details
- Highest Development Stage:
Phase 2 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















